Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Selatogrel · ACT-246475, ACT-246575

Small molecule · Antagonist of P2Y12 receptor (P2RY12) · developed by Viatris Innovation GmbH

Phase 2 Most advanced trial (none active)
VTRS Developer
3 Registered trials

What is Selatogrel?

Selatogrel is a reversible P2Y12 receptor antagonist given subcutaneously. It blocks the P2Y12 receptor on platelets, inhibiting platelet activation and aggregation. It is studied in stable coronary artery disease and acute myocardial infarction.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ACT-246475, ACT-246575
Drug type
Small molecule
Targets
P2Y12 receptor (P2RY12)
Mechanism
Antagonist of P2Y12 receptor (P2RY12)
Pathways
platelet aggregation
Therapy area
Cardiovascular
Developer
Viatris Innovation GmbH (VTRS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
6DPK7O4PR7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03487445 Phase 2 Acute Myocardial Infarction Completed VTRS
NCT03384966 Phase 2 Stable Coronary Artery Disease Completed VTRS
NCT03814200 Phase 1 Healthy Subject Completed VTRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myocardial InfarctionHealthy SubjectStable Coronary Artery Disease

Other drugs acting on P2RY12

More from Viatris Innovation GmbH

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VTRS page.

Follow VTRS, the company behind Selatogrel

See VTRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VTRS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.